This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
News|Articles|September 1, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-09-07-2016
- Volume 11
- Issue 9
Eppendorf Expands Single-Use Vessel Portfolio
Author(s)Pharmaceutical Technology Editors
The company announced that it will be expanding its portfolio of single-use vessels for fermentation.
On July 5, 2016, Eppendorf announced that it would be expanding its portfolio of rigid-wall single-use vessels for fermentation. According to the company, the Eppendorf BioBLU 3f was developed specifically for microbial bioprocessing in working volumes of 1.25 to 3.75 L, extending the full range of operation for single-use fermentation from 60 mL to 3.75 L.
Eppendorf BioBLU f Single-Use Vessels specifically address the demands of high cell density fermentation of bacteria, yeasts, and fungi. Magnetic overhead drives featuring impellers support agitation rates up to 1200 rpm and provide high-performance mass transfer. The integrated cooling baffles enable efficient heat removal for exothermic processes and the rigid-wall industrial stirred-tank design ensures scalability and simplifies technology transfer.
Source: Eppendorf
Articles in this issue
about 10 years ago
Putting Shelf-Life to the Testabout 10 years ago
The Enzymatic Catalysis Route to Going Greenabout 10 years ago
CMOs Step Up to Test New Bioprocessing Technologyabout 10 years ago
SGS Opens New Facility in Wiesbaden, Germanyabout 10 years ago
CSafe Acquires Kalliboxabout 10 years ago
CordenPharma in France Reports Successful FDA Inspectionabout 10 years ago
Automated Infrared Microscope Effectively Analyzes Micro Samplesabout 10 years ago
Copley Scientific Launches Products for Tablet Dissolution Testingabout 10 years ago
PANalytical launches the Empyrean Nano editionabout 10 years ago
Fuji Health Changes Name to Fuji Chemical Industries USA, Inc.Related to this article
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.